GTBP: Multiplikator rega marang pendapatan GT Biopharma Corporation

Simbol lan logo merek GT Biopharma Inc (GTBP)

GT Biopharma, Inc. (GTBP) utilizes cGMP facilities for protein production to minimize supply chain risks. The innovative TriKE platform directs immunity toward tumors, outperforming standard therapy. Engaging CRO vendors for clinical trials while maintaining full patent ownership eliminates external dependency. P/S volatility helps align market value with revenue, with the parameter stabilizing at .

GTBP - Kapitalisasi marang pendapatan gtbiopharma.com ing rentang 04.07.2022 - 14.11.2026

Rincian analitis perusahaan GT Biopharma Corp (GTBP)

- rega saham lan target rega konsensus:
Kurs saham gtbiopharma.com|GTBP - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar GT Biopharma Corp|GTBP - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- data kapitalisasi buku:
Rega Buku Saham GT Biopharma|GTBP - Aset Bersih Perusahaan|Nilai Pasar marang Nilai Buku gtbiopharma.com|GTBP - Total Aset Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas GT Biopharma, Inc.|GTBP - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal GT Biopharma Corporation|GTBP - Utang perusahaan|Utang-utang marang nilai buku GT Biopharma Corp|GTBP - Utang jangka dawa perusahaan|Kewajiban jangka cendhak GT Biopharma|Rasio jangkoan perantara gtbiopharma.com
- statistik bathi lan rasio pasar:
GTBP - Bathi resik|Proyeksi bathi mangsa ngarep GT Biopharma, Inc.|GTBP - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi GT Biopharma Inc|GTBP - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan GT Biopharma Corp|GTBP - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) GT Biopharma|GTBP - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan gtbiopharma.com|GTBP - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep GT Biopharma, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
GTBP - Pendapatan perusahaan|Prakiraan pendapatan perusahaan gtbiopharma.com|GTBP - Multiplikator P/S|Multiplikator forward rega marang pendapatan GT Biopharma Corp
Analisis fundamental perusahaan:GTBP - gtbiopharma.com
Sampel barang GT Biopharma, Inc.

The market value dynamics of GT Biopharma, Inc. (GTBP) relative to its operating income allow for an assessment of business resilience to volatility, particularly given the risks of capital dilution and drug toxicity. By analyzing the price-to-sales ratio, an investor can determine how much the market is willing to pay per unit of sales, which helps identify asset overvaluation amid fierce competition in the cancer immunotherapy sector.

Pesaing GT Biopharma, Inc.

tgtherapeutics.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ACLX (Arcellx, Inc.)|Multiplikator rega marang pendapatan Disc Medicine Inc|SNDX: Kapitalisasi marang pendapatan|Kura - Kapitalisasi marang volume dodolan|ADCT (ADC Therapeutics) - Kapitalisasi marang pendapatan|Foghorn Therapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|VOR (Vor Biopharma) - Multiplikator P/S|Rasio rega marang pendapatan NKTX|Multiplikator P/S COEP|Koefisien rega marang pendapatan Actinium Corp|Rasio rega marang pendapatan Estrella Immunopharma ESLA|CASI Pharmaceuticals Inc. (CASI) - Rega marang dodolan|MRKR - Rasio rega marang pendapatan|Rasio rega marang dodolan INAB|ERNA: Multiplikator P/S|Aptose Biosciences - Rasio kapitalisasi pasar marang pendapatan|BPTH (Bio-Path Holdings) - Multiplikator P/S|Multiplikator P/S meipharma.com|Rasio rega marang pendapatan Vincerx Pharma, Inc. (VINC)